Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Testing Method Predicts Trauma Patient Recovery Days in Advance

By LabMedica International staff writers
Posted on 16 Feb 2026

Trauma patients with nearly identical injuries often experience very different recoveries, even when treated similarly. More...

Traditional assessments based on injury severity do not always explain why some patients develop organ failure or die while others recover. This unpredictability limits doctors’ ability to intervene early and tailor care. Now, a new study shows that analyzing molecular signals in blood can predict recovery trajectories and complications days before they appear.

Researchers at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a first-of-its-kind study using “omics” technologies, combining proteomics and metabolomics to examine biological signals in trauma patients’ blood. The team mapped molecular endotypes and recovery trajectories in more than 1,300 trauma patients over time. By analyzing patterns of proteins and metabolites, researchers were able to characterize each patient’s biological response to injury rather than relying solely on physical injury scores.

The results showed that organ failure and mortality could be predicted more accurately and efficiently using omics markers than with traditional injury-based measures. The predictive models achieved 92% accuracy and were validated in an independent cohort of more than 300 trauma patients. The findings, published in Science Translational Medicine, demonstrate that molecular profiling can reveal why patients with similar injuries experience different outcomes, enabling earlier and more precise risk assessment.

Researchers say the approach lays the groundwork for personalized trauma care in real-time emergency settings. Efforts are now underway to adapt the molecular profiling system for rapid, point-of-care testing in emergency departments and military environments. The findings are also expected to influence the design of future clinical trials, including a trial evaluating fibrinogen supplementation. Investigators believe this strategy could support the development of targeted therapies and reshape trauma treatment planning.

"Two patients often arrive in the ER with nearly identical injuries but go on to have widely divergent outcomes despite similar care,” said Mitchell Cohen, senior author and professor of surgery at CU Anschutz. “This occurs because their biologic response to injury and treatment is different. Our novel approach and modeling allows us to see those differences in real time, so we can know their biologic state, predict their trajectories and tailor their treatments in a personalized manner.”

Related Links:
CU Anschutz 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.